| Literature DB >> 22046296 |
Lina Ma1, Yanyan Huang, Wangyu Zhu, Shiquan Zhou, Jihang Zhou, Fang Zeng, Xiaoguang Liu, Yongkui Zhang, Jun Yu.
Abstract
Using DNA microarrays, we generated both mRNA and miRNA expression data from 6 non-small cell lung cancer (NSCLC) tissues and their matching normal control from adjacent tissues to identify potential miRNA markers for diagnostics. We demonstrated that hsa-miR-96 is significantly and consistently up-regulated in all 6 NSCLCs. We validated this result in an independent set of 35 paired tumors and their adjacent normal tissues, as well as their sera that are collected before surgical resection or chemotherapy, and the results suggested that hsa-miR-96 may play an important role in NSCLC development and has great potential to be used as a noninvasive marker for diagnosing NSCLC. We predicted potential miRNA target mRNAs based on different methods (TargetScan and miRanda). Further classification of miRNA regulated genes based on their relationship with miRNAs revealed that hsa-miR-96 and certain other miRNAs tend to down-regulate their target mRNAs in NSCLC development, which have expression levels permissive to direct interaction between miRNAs and their target mRNAs. In addition, we identified a significant correlation of miRNA regulation with genes coincide with high density of CpG islands, which suggests that miRNA may represent a primary regulatory mechanism governing basic cellular functions and cell differentiations, and such mechanism may be complementary to DNA methylation in repressing or activating gene expression.Entities:
Mesh:
Substances:
Year: 2011 PMID: 22046296 PMCID: PMC3203153 DOI: 10.1371/journal.pone.0026502
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Enriched GO terms for biological process based on variable genes in lung cancer tissues when compared with their adjacent normal tissues.
| Class | GO terms | GO number | Statistic |
|
| DNA metabolic process | GO:0006259 | C = 552;O = 27;E = 9.68;R = 2.79;rawP = 1.48e-06;adjP = 0.0008 |
|
| M phase | GO:0000279 | C = 370;O = 21;E = 6.49;R = 3.24;rawP = 2.35e-06;adjP = 0.0008 |
|
| immune response | GO:0006955 | C = 750;O = 101;E = 42.54;R = 2.37;rawP = 1.51e-16;adjP = 2.91e-13 |
|
| immune system process | GO:0002376 | C = 1066;O = 124;E = 60.46;R = 2.05;rawP = 3.98e-15;adjP = 3.84e-12 |
|
| defense response | GO:0006952 | C = 657;O = 89;E = 37.26;R = 2.39;rawP = 8.14e-15;adjP = 5.23e-12 |
|
| inflammatory response | GO:0006954 | C = 359;O = 60;E = 20.36;R = 2.95;rawP = 2.82e-14;adjP = 1.36e-11 |
|
| response to wounding | GO:0009611 | C = 560;O = 75;E = 31.76;R = 2.36;rawP = 2.23e-12;adjP = 8.60e-10 |
|
| response to stress | GO:0006950 | C = 1696;O = 147;E = 96.19;R = 1.53;rawP = 5.52e-08;adjP = 1.33e-05 |
|
| innate immune response | GO:0045087 | C = 176;O = 30;E = 9.98;R = 3.01;rawP = 5.52e-08;adjP = 1.33e-05 |
|
| response to external stimulus | GO:0009605 | C = 904;O = 91;E = 51.27;R = 1.77;rawP = 4.51e-08;adjP = 1.33e-05 |
|
| immune effector process | GO:0002252 | C = 200;O = 31;E = 11.34;R = 2.73;rawP = 3.06e-07;adjP = 6.56e-05 |
|
| regulation of immune system process | GO:0002682 | C = 362;O = 45;E = 20.53;R = 2.19;rawP = 5.72e-07;adjP = 0.0001 |
|
| leukocyte mediated immunity | GO:0002443 | C = 126;O = 22;E = 7.15;R = 3.08;rawP = 2.14e-06;adjP = 0.0002 |
|
| actin cytoskeleton organization | GO:0030036 | C = 257;O = 35;E = 14.58;R = 2.40;rawP = 1.28e-06;adjP = 0.0002 |
|
| positive regulation of immune system process | GO:0002684 | C = 229;O = 32;E = 12.99;R = 2.46;rawP = 2.08e-06;adjP = 0.0002 |
|
| lymphocyte activation | GO:0046649 | C = 272;O = 36;E = 15.43;R = 2.33;rawP = 1.80e-06;adjP = 0.0002 |
|
| T cell activation | GO:0042110 | C = 194;O = 29;E = 11.00;R = 2.64;rawP = 1.57e-06;adjP = 0.0002 |
|
| leukocyte activation | GO:0045321 | C = 324;O = 41;E = 18.38;R = 2.23;rawP = 1.15e-06;adjP = 0.0002 |
|
| actin filament-based process | GO:0030029 | C = 274;O = 36;E = 15.54;R = 2.32;rawP = 2.14e-06;adjP = 0.0002 |
|
| adaptive immune response | GO:0002250 | C = 113;O = 20;E = 6.41;R = 3.12;rawP = 4.97e-06;adjP = 0.0005 |
|
| adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains | GO:0002460 | C = 112;O = 20;E = 6.35;R = 3.15;rawP = 4.31e-06;adjP = 0.0005 |
|
| lymphocyte mediated immunity | GO:0002449 | C = 106;O = 19;E = 6.01;R = 3.16;rawP = 7.04e-06;adjP = 0.0007 |
|
| positive regulation of biological process | GO:0048518 | C = 1865;O = 148;E = 105.77;R = 1.40;rawP = 9.03e-06;adjP = 0.0008 |
|
| cell activation | GO:0001775 | C = 366;O = 42;E = 20.76;R = 2.02;rawP = 1.05e-05;adjP = 0.0009 |
*The alst column lists the number of reference genes in the category (C), number of genes in the gene set and also in the category (O), expected number in the category (E), Ratio of enrichment (R), p value from hypergeometric test (rawP), and p value adjusted by the multiple test adjustment (adjP).
Enriched GO terms for cellular components based on variable genes in lung cancer tissues when compared with their adjacent normal tissues.
| Class | GO terms | GO number | Statistic |
|
| chromosome | GO:0005694 | C = 454;O = 26;E = 8.45;R = 3.08;rawP = 3.99e-07;adjP = 5.35e-05 |
|
| chromosomal part | GO:0044427 | C = 378;O = 23;E = 7.03;R = 3.27;rawP = 6.77e-07;adjP = 5.35e-05 |
|
| chromosome, centromeric region | GO:0000775 | C = 120;O = 11;E = 2.23;R = 4.93;rawP = 1.48e-05;adjP = 0.0008 |
|
| plasma membrane part | GO:0044459 | C = 1918;O = 169;E = 104.66;R = 1.61;rawP = 7.90e-11;adjP = 2.21e-08 |
|
| integral to plasma membrane | GO:0005887 | C = 1183;O = 112;E = 64.55;R = 1.74;rawP = 4.46e-09;adjP = 6.24e-07 |
|
| plasma membrane | GO:0005886 | C = 3650;O = 269;E = 199.17;R = 1.35;rawP = 1.34e-08;adjP = 9.38e-07 |
|
| intrinsic to plasma membrane | GO:0031226 | C = 1206;O = 112;E = 65.81;R = 1.70;rawP = 1.30e-08;adjP = 9.38e-07 |
|
| membrane part | GO:0044425 | C = 6381;O = 417;E = 348.19;R = 1.20;rawP = 7.79e-07;adjP = 3.64e-05 |
|
| membrane | GO:0016020 | C = 7186;O = 462;E = 392.12;R = 1.18;rawP = 7.05e-07;adjP = 3.64e-05 |
|
| I-kappaB/NF-kappaB complex | GO:0033256 | C = 4;O = 4;E = 0.22;R = 18.33;rawP = 8.81e-06;adjP = 0.0004 |
|
| lytic vacuole | GO:0000323 | C = 206;O = 27;E = 11.24;R = 2.40;rawP = 2.13e-05;adjP = 0.0006 |
|
| intrinsic to membrane | GO:0031224 | C = 5451;O = 355;E = 297.44;R = 1.19;rawP = 1.80e-05;adjP = 0.0006 |
|
| lysosome | GO:0005764 | C = 206;O = 27;E = 11.24;R = 2.40;rawP = 2.13e-05;adjP = 0.0006 |
|
| cell-substrate adherens junction | GO:0005924 | C = 100;O = 17;E = 5.46;R = 3.12;rawP = 2.67e-05;adjP = 0.0007 |
*The last column lists the number of reference genes in the category (C), number of genes in the gene set and also in the category (O), expected number in the category (E), Ratio of enrichment (R), p value from hypergeometric test (rawP), and p value adjusted based on the multiple test adjustment (adjP).
Figure 1Down-regulated target candidates of hsa-miR-96 in NSCLC.
(A) Microarray results of the Down-regulated target candidates of hsa-miR-96 in NSCLC. We assayed 6 paired NSCLC vs. normal tissue. C and N stand for cancer and adjacent normal tissue, respectively. The asterisk marks genes belong to the correlated group and the remaining genes are grouped into the anti-correlated group according to the expression relationship of these genes with their regulatory miRNAs. (B) Validation of microarray results by qRT-PCR. We selected 10 down-regulated target candidates of hsa-miR-96 and performed qRT-PCR experiments for the validation of relative mRNA expression in reference to glyceraldehyde-3-phosphate dehydrogenase (GAPDH). The relative expression values are the means ± SE. *, P<0.05 by t test; **, P<0.001 by t test.
Figure 2Quantitative RT-PCR analysis of hsa-miR-96 expression.
Two groups of comparisons were performed: (1) tumor vs. adjacent normal lung tissues, and (2) cancer serum vs. non-cancer serum. Relative hsa-miR-96 expression was determined in reference to an internal U6 snRNA control. Relative expression values are the normalized mean ± SE.
Figure 3miRNA regulation analysis.
We classified all expression-variable mRNAs during lung cancer development based on their relationship with miRNAs. The results are classified into correlated, anti-correlated, and others (no correlation). The correlated mRNAs show correlated expressions to their regulatory miRNA expressions and the anti-correlated mRNAs are not. Three different methods were used to predict potential miRNA targets: “Conserved” are those genes that have conserved miRNA binding sites among vertebrates or mammals, and these genes were predicted by using the P CT method of TargetScan; “TargetScan” are those genes that are predicted by using a perl script of TargetScan without considering conservation. “miRanda” are those genes that are predicted potential targets based on miRanda v3.3a on Linux platform. (A) Gene distribution of the correlated and anti-correlated mRNAs was plotted based on their miRNA regulation values. (B) Gene distribution of the three groups of mRNAs was plotted based on their expression values. The expression value was defined by referencing that of the adjacent normal tissue (log2). (C) The relationship between gene expression and miRNA regulation.
Three groups of mRNAs predicted with different methods.
| miRanda | TargetScan | Conserved | ||
|
|
| 482 | 472 | 197 |
|
| 53(9.12%) | 55(9.47%) | 26(4.48%) | |
|
| 429(33.08%) | 417(32.15%) | 171(13.18%) | |
|
|
| 294 | 285 | 190 |
|
| 117(20.14%) | 108(18.59%) | 50(8.61%) | |
|
| 177(13.65%) | 177(13.65%) | 140(10.97%) | |
|
|
| 1102 | 1121 | 1491 |
|
| 411(70.74%) | 418(71.94%) | 505(86.92%) | |
|
| 691(53.28%) | 703(54.2%) | 986(76.02%) |
*The proportion was calculated by dividing the number of all up-regulated mRNAs or down-regulated mRNAs.
Figure 4Potential relationship between miRNA and DNA methylation.
(A) The distribution of CpG-density classified genes in each group. These target genes were predicted using three different methods: “Conserved” are those genes that have conserved miRNA binding sites among vertebrates or mammals, and these genes were predicted by using the P CT method of TargetScan; “TargetScan” are those genes that are predicted by using a perl script of TargetScan without considering conservation. “miRanda” are those genes that are predicted potential targets based on miRanda v3.3a on Linux platform. (B) Relationship between CpG island density and gene expression. Three groups were classified: all expressed genes in NSCLC, the miRNA-regulated genes, and other genes which may not be influenced by miRNAs.
Figure 5Different GO terms between the miRNA-regulated and miRNA-unregulated genes.
P<0.05 was considered as significant [67].